Forecasted · Cooperative Agreement
Continuing Enhanced National Surveillance for Prion Diseases in the United States
Centers for Disease Control - NCEZID, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Continuing Enhanced National Surveillance for Prion Diseases in the United States
- Issuing agency
- Centers for Disease Control - NCEZID (Department of Health and Human Services)
- Opportunity number
- CDC-RFA-CK-27-0046
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close March 27, 2027 (agency estimate)Agency note: Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date.
- Agency estimates
- Estimated posting: December 29, 2026. Estimated award date: August 31, 2027. Estimates can change.
- Published award range
- $3,000,000 – $25,000,000
- Estimated total program funding
- $25,000,000
- Expected number of awards
- 1
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (open to any type of entity, subject to any clarification in Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov lists eligibility as Unrestricted. Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.317
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363153 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363153 · Funding opportunity number CDC-RFA-CK-27-0046
- Posted
- July 10, 2026 · Source last updated July 10, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: eligibility criteria text.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Description (from the official listing)
The CDC announces the availability of FY 2027 funds for a cooperative agreement to continue enhanced national surveillance for human prion diseases, also known as transmissible spongiform encephalopathies (TSEs), in the United States. The purpose is to continue an active surveillance program to help confirm suspected and clinically diagnosed cases of human prion disease and to monitor the occurrence of potentially emerging human prion diseases in the United States. Outcomes are enhanced national surveillance for always fatal human prion diseases through improved diagnoses and continued monitoring for emerging or new prion diseases in the United States. These outcomes are accomplished through the funding of a specialized center to conduct state-of-the-art diagnostic techniques. Prion diseases can only be confirmed through brain tissue analyses, and many facilities lack the expertise and/or the willingness, due to infection control concerns, to handle and accurately diagnose specimens from suspected cases. Since 1997, the Centers for Disease Control and Prevention (CDC) has funded a center to provide prion disease diagnostic services, which has allowed for disease confirmation, evaluation of disease trends over time, and identification of disease subtypes. Data have been shared with CDC experts who partner with center staff, providing guidance and epidemiological knowledge. This collaboration has contributed to accurate national surveillance findings and helped to provide confidence that novel prion diseases, such as a human form of the animal prion disease, chronic wasting…
Read the full description
The CDC announces the availability of FY 2027 funds for a cooperative agreement to continue enhanced national surveillance for human prion diseases, also known as transmissible spongiform encephalopathies (TSEs), in the United States. The purpose is to continue an active surveillance program to help confirm suspected and clinically diagnosed cases of human prion disease and to monitor the occurrence of potentially emerging human prion diseases in the United States. Outcomes are enhanced national surveillance for always fatal human prion diseases through improved diagnoses and continued monitoring for emerging or new prion diseases in the United States. These outcomes are accomplished through the funding of a specialized center to conduct state-of-the-art diagnostic techniques. Prion diseases can only be confirmed through brain tissue analyses, and many facilities lack the expertise and/or the willingness, due to infection control concerns, to handle and accurately diagnose specimens from suspected cases. Since 1997, the Centers for Disease Control and Prevention (CDC) has funded a center to provide prion disease diagnostic services, which has allowed for disease confirmation, evaluation of disease trends over time, and identification of disease subtypes. Data have been shared with CDC experts who partner with center staff, providing guidance and epidemiological knowledge. This collaboration has contributed to accurate national surveillance findings and helped to provide confidence that novel prion diseases, such as a human form of the animal prion disease, chronic wasting disease, have not been occurring in the country.
Agency contact
Lisa Angel
langel@cdc.gov